

Kanjinti[™] (trastuzumab-anns) – First-time biosimilar launch

- On July 19, 2019, <u>Allergan and Amgen announced the launch</u> of <u>Kanjinti (trastuzumab-anns)</u>, a biosimilar to Genentech's <u>Herceptin (trastuzumab)</u>.
 - Mylan's Ogivri® (trastuzumab-dkst) was the first biosimilar to Herceptin and was approved in December 2017. In December 2018, Teva and Celltrion's Herceptin biosimilar, Herzuma® (trastuzumab-pkrb), was approved. Samsung Bioepis and Merck's Ontruzant® (trastuzumab-dttb) was approved in January 2019. Pfizer's Trazimera™ (trastuzumab-qyyp) was approved in March 2019.
 - Mylan, Teva/Celltrion, Samsung Bioepis/Merck, and Pfizer's launch plans for Ogivri, Herzuma, Ontruzant, and Trazimera are pending.
- Kanjinti and Herceptin share the following indications:
 - Adjuvant breast cancer: adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature) breast cancer as part of a treatment regimen consisting of <u>doxorubicin</u>, <u>cyclophosphamide</u>, and either <u>paclitaxel</u> or <u>docetaxel</u>; or as part of a treatment regimen with docetaxel and <u>carboplatin</u>; or as a single agent following multi-modality anthracycline based therapy.
 - Metastatic breast cancer: in combination with paclitaxel for first-line treatment of HER2overexpressing metastatic breast cancer; or as a single agent for treatment of HER2 overexpressing breast cancer in patients who have received ≥ 1 chemotherapy regimens for metastatic disease.
 - Metastatic gastric cancer: in combination with <u>cisplatin</u> and <u>capecitabine</u> or <u>5-fluorouracil</u>, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.
 - Patients should be selected for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.
- Similar to Herceptin, Kanjinti carries a boxed warning for cardiomyopathy, infusion reactions, embryo-fetal toxicity, and pulmonary toxicity.
- The wholesale acquisition cost (WAC) of Kanjinti is \$3,697.26 per 420 mg multi-dose vial. This is 15% lower than the WAC for Herceptin.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.